A.R. AMIROV^1,2

¹Kazan State Medical Academy — Branch Campus of  RMACPE MH Russia, Kazan

²Republican Clinical Hospital, Kazan

  Contact details:

Amirov A.R. — postgraduate student of the Department of Urology and Nephrology, doctor of the Department Kidney Transplantation

Address: 36 Butlerov Str., Kazan, Russian Federation, 420012, tel. +7-967-461-39-33, e-mail: anvar.xl@gmail.com

 Objective — to analyze the modern Russian and foreign publications on methods of conservative treatment of overactive bladder.

Materials and methods. Analysis of the modern Russian and foreign publications (including Cochrane reviews) on overactive bladder pharmacotherapy, which includes oral and transdermal forms of M-cholinoblockers and beta-3-adrenomimetics.

Results. The results are described of the Cochrane database study related to the application of M-cholinoblockers and agonists of beta-3-adrenoreceptors. This provides understanding of the currently available evidence for the safety and clinical efficacy of overactive bladder pharmacotherapy.

Conclusion. Anticholinergic drugs and beta-3-adrenergic agonists are the basis of overactive bladder pharmacotherapy. The therapy should be selected individually, taking into account all the features of the patient.

Key words: neurogenic bladder, overactive bladder, M-cholinolytics, beta-3 adrenoreceptor agonists, recommendations.

(For citation: Amirov A.R. Methods for conservative treatment of overactive bladder in women. Practical medicine. 2019. Vol. 17, № 4, P. 20-23)

REFERENCES

1. Apolikhina I.A. et al. Modern possibilities of drug treatment of overactive bladder in women. Meditsinskiy sovet, 2017, no. 2, pp. 122-127 (in Russ.).
2. Gadzhieva Zh.K. Narusheniya mocheispuskaniya: rukovodstvo, pod red. Alyaeva Yu.G. [Disorders of urination: a guide. Ed. by Alyaev Yu.G.]. Moscow: GEOTAR-Media, 2010. 176 p.
3. Roxana G. Treatments for Overactive Bladder: Focus on Pharmacotherapy. JOGC, 2012, vol. November, pp. 1092-1101.
4. Loran O.B. Epidemiologiya, etiologiya, patogenez, diagnostika nederzhaniya mochi. Plenum Pravleniya Rossiyskogo obshchestva urologov: materialy [Epidemiology, etiology, pathogenesis, diagnosis of urinary incontinence. Plenum of the Board of the Russian Society of Urology: Materials]. Moscow, 2001. Pp. 2-41.
5. Bump R.C. Discussion: Epidemiology of urinary incontinence. Urology, 1997, 50 (6A), pp. 15-16.
6. Al’-Shukri S.Kh., Ananiy I.A., Amdiy R.E., Kuz’min I.V. Electrical stimulation of the pelvic floor muscles in the treatment of patients with urinary incontinence after radical prostatectomy. Urologicheskie vedomosti, 2016, vol. 6, no. 4, pp. 10-13 (in Russ.).
7. Apolikhina I.A. Klinicheskaya epidemiologiya, differentsial’naya diagnostika i konservativnoe lechenie nederzhaniya mochi u zhenshchin: avtoref. dis. … d-ra med. nauk [Clinical epidemiology, differential diagnosis and conservative treatment of urinary incontinence in women. Synopsis of dis. Dr med. sciences]. Moscow, 2006.
8. Danilov V.V., Luchinskiy S.A., Danilova T.I., Danilov V.V. Female sexual dysfunctions and disorders of urination. Ginekologiya, 2013, vol. 15, no. 3, pp. 58-61 (in Russ.).
9. Romikh V.V. Urinary incontinence and LUTS in patients after treatment of prostate cancer. Eksperimental’naya i klinicheskaya urologiya, 2011, no. 2-3, pp. 85-87 (in Russ.).
10. Chamberlain J.D., et al. Mortality and longevity after a spinal cord injury: systematic review and meta-analysis. Neuroepidemiology, 2015, 44, p. 182.
11. Stohrer M., et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur. Urol., 2009, 56, p. 81.
12. Jamil F. Towards a catheter free status in neurogenic bladder dysfunction: a review of bladder management options in spinal cord injury (SCI). Spinal Cord, 2001, 39, p. 355.
13. Nabi G., Cody J.D., Ellis G., Hay-Smith J., Herbison G.P. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst. Rev., 2009. (1): CD 003781.
14. Madersbacher H., et al. Neurogenic detrusor over activity in adults: are view on efficacy, to lerability and safety of oral antimuscarinics. Spinal Cord, 2013, 51, p. 432.
15. Madhuvrata P., et al. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur. Urol, 2012, 62, p. 816.
16. Kennelly M.J., et al. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology, 2009, 74, p. 741.
17. Andersson K.E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol, 2004, 3, pp. 46-53.
18. Staskin D.R., Dmochowski R.R., Sand P.K., et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo-controlled, multicenter study. J. Urol., 2009, 181, pp. 1764-72.
19. Sand P., Zinner N., Newman D., Lucente V., et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: amulti centre, community-based, randomized study. BJU Int, 2007, 99 (4), pp. 836-44.
20. Mahanta K., et al. Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defect shaving cys to metricab normalities. J. Pediatr. Urol, 2008, 4, p. 118.
21. Biastre K., Burnakis T. Trospium chloride treatment of over active bladder. Ann. Pharmacother, 2009, 43 (2), pp. 283-95.
22. Van Rey F., et al. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv. Urol, 2011, 834753.
23. Herschorn S., Stothers L., Carlson K., et al. Tolerability of 5 mg solifenacinonce daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J. Urol, 2010, 183 (5), pp. 1892-8.
24. Wesnes K.A., Edgar C., Tretter R.N., Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single dose of solifenacin 10 mg. Expert Opin Drug Saf, 2009, 8 (6), pp. 615-26.
25. Olshansky B., Ebinger U., Brum J., et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacinin healthy participants > or = 50 years. J. Cardiovasc. Pharmacol. Ther, 2008, 13 (4), pp. 241-51.
26. Khullar V., Amarenco G., Angulo J.C. et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur. Urol., 2013, 63 (2), pp. 283-295.
27. Nardulli R. et al. Combined antimuscarinics for treatment of neurogenic overactive bladder. Int. J. Immunopathol. Pharmacol, 2012, 25, p. 35s.
28. Alhasso A.A., McKinlay J., Patrick K., Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst. Rev, 2006. (2): CD 003193.
29. Hay-Smith J., Ellis G., Herbison G.P. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst. Rev, 2009. (1):CD005429.
30. Zinner N., Tuttle J., Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J. Urol, 2005, 23, pp. 248-52.
31. Herschorn S., Swift S., Guan Z., et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-ontrolled trial. BJU Int, 2010, 105 (1), pp. 58-66.
32. Wilson N.M., Hilmer S.N., March L.M. et al. Associations between drug burden index and falls in older people in residential aged care. J. Am. Geriatr. Soc, 2011, 59 (5), pp. 875-80.
33. Leong R.K., De Wachter S.G., van Kerrebroeck P.E. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol. Int, 2010, 84 (3), pp. 245-53.
34. Brazzelli M., Murray A., Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge in continence: a systematic review. J. Urol, 2006, 175 (3 Pt 1), pp. 835-41.
35. Peters K.M., Macdiarmid S.A., Wooldridge L.S., et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J. Urol, 2009, 182 (3), pp. 1055-61.